Mutation in the V2 vasopressin receptor gene, AVPR2, causes nephrogenic syndrome of inappropriate diuresis [PDF]
, 2015 Nephrogenic syndrome of inappropriate antidiuresis (NSIAD) is a recently discovered rare disease caused by gain-of-function mutations of the V2 vasopressin receptor gene, AVPR2.
Balla, András +7 more
core +2 more sources
Tolvaptan, hyponatremia, and heart failure
International Journal of Nephrology and Renovascular Disease, 2011 Tolvaptan is the first FDA-approved oral V(2) receptor antagonist for the treatment of euvolemic and hypervolemic hyponatremia, in patients with conditions associated with free water excess such as heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone secretion.
Hammam Zmily +2 more
openaire +4 more sources
Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy. [PDF]
, 2020 Arginine vasopressin (AVP) and its type-2 receptor (V2R) play an essential role in the regulation of salt and water homeostasis by the kidneys. V2R activation also stimulates proliferation of renal cell carcinoma (RCC) cell lines in vitro.
Calvet, James P +10 more
core
Interventions for chronic non-hypovolaemic hypotonic hyponatraemia (Review) [PDF]
, 2018 Background : Chronic (present > 48 hours) non-hypovolaemic hyponatraemia occurs frequently, can be caused by various conditions, and is associated with shorter survival and longer hospital stays.
Craig, Jonathan C +5 more
core +2 more sources
Preclinical efficacy of [V 4 Q 5 ]dDAVP, a second generation vasopressin analog, on metastatic spread and tumor-associated angiogenesis in colorectal cancer [PDF]
, 2018 Purpose Control of metastatic spread of colorectal cancer (CRC) remains as a major therapeutic challenge. [V 4 Q 5 ]dDAVP is a vasopressin peptide analog with previously reported anticancer activity against carcinoma tumors.
Alonso, Daniel Fernando +6 more
core +1 more source
Unveiling some FDA-approved drugs as inhibitors of the store-operated Ca2+ entry pathway. [PDF]
, 2017 The store-operated calcium entry (SOCE) pathway is an important route for generating cytosolic Ca2+ signals that regulate a diverse array of biological processes.
Rahman, Saifur, Rahman, Taufiq
core +2 more sources
Improving Postdischarge Outcomes in Acute Heart Failure [PDF]
, 2018 The global burden that acute heart failure (AHF) carries has remained unchanged over the past several decades (1). European registries (2–5) showed that 1-year outcome rates remain unacceptably high (Table 1) and confirm that hospitalization for AHF ...
Ambrosy, Andrew P. +8 more
core +1 more source
Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes [PDF]
, 2016 Tolvaptan is a selective V2-receptor antagonist primarily metabolized by CYP 3A. The present study investigated the hepatocellular disposition of tolvaptan and the generated tolvaptan metabolites, DM-4103 and DM-4107, as well as the potential for drug ...
Brock, William J. +7 more
core +2 more sources
Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function [PDF]
, 2013 The selective vasopressin V2–receptor antagonist tolvaptan is eliminated almost exclusively by non-renal mechanisms. As renal impairment can influence the pharmacokinetics of drugs even when eliminated by non-renal mechanisms, we evaluated the effect of ...
Bricmont, Patricia +2 more
core +1 more source
Vasopressin Antagonism in Heart Failure [PDF]
, 2005 Treatment of chronic heart failure (HF) is based on interference with the renin-angiotensin-aldosterone system and the adrenergic nervous system. Diuretics are used in volume-expanded patients.
Gheorghiade, Mihai, Goldsmith, Steven R.
core +1 more source